Appointment supports Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions
Quotient Clinical, the drug development services provider, has appointed Azhar Kalim as Chief Commercial Officer (CCO).
Kalim will lead the enhanced commercial team in a new role, with a focus on supporting Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions.
Quotient’s integrated capabilities incorporate formulation development, GMP drug product manufacturing and early stage clinical trials.
The acquisitions of SeaView Research, a specialist early phase clinical pharmacology business; and QS Pharma, a small molecule formulation development and manufacturing business, were announced in February.
Kalim has more than 25 years’ experience in the drug development services sector. He will be responsible for global commercial activities to support Quotient’s integrated services.
Kalim will be instrumental in directing the global commercial team in terms of strategic marketing, business development, innovation, key account management and customer service to biotech and pharmaceutical clients across the globe.